spacer
home > ict > spring 2018 > perfecting performance
PUBLICATIONS
International Clinical Trials

Perfecting Performance

The integration of the new ICH E6 (R2) guideline has created many contradictory opinions about what is necessary to be implemented as sponsor oversight in clinical trials to fulfil its requirements. Of course, sponsor oversight in general is not new, but the details to perform mandatory oversight activities and manage compliance for all clinical trial activities are still raising discussions with different opinions and solutions.

Smaller sponsor, biopharmaceutical, and medical device companies moving into early phase clinical trials are especially struggling with the definition and integration of effective study oversight to manage the quality of their research.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gabriele Faist has more than 28 years' pharma industry experience, with 25 years working in CROs. At the CRO, she was responsible for overseeing clinical drug development programmes, which included line management of a group made up of more than 20, including Project Leaders, Senior Project Leaders, and even Project Assistants, as well as project-related leadership of worldwide multi-functional teams to effectively implement projects, tracking the programme progress to ensure that they are being completed on time and within budget, and maintaining the quality of all work within them.

Heike Schön has more than 25 years of experience in leadership positions in international clinical research and drug development in CROs and biotechnology companies. She has a profound knowledge of clinical drug development processes and regulatory requirements from first-in-human trials to market access. As General Manager, she gained experience in leading and developing a CRO and has successfully implemented her own company, LUMIS International, as Co-Founder and Managing Director. One of her main activities is to support small biotech companies in setting up their clinical
spacer
Gabriele Faist
spacer
spacer
spacer
Heike Schön
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement